BioMark Dx, TMIC Partner on Cancer Metabolomics Research

Mar 27, 2015

|

NEW YORK (GenomeWeb) – BioMark Diagnostics today announced it is partnering with The Metabolomics Innovation Centre on cancer research.

The deal augments BioMark's efforts to discover, validate, and translate metabolomics-based diagnostic tests for early cancer detection, the Vancouver, British Columbia-based firm said, adding it "complements" its planned research into lung, prostate, breast, and colon cancer.

In collaboration with TMIC, BioMark plans to develop novel point-of-care diagnostic tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Main menu